[1] Matsuo, et al. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am.J.Clin.Nutr. 55(1 Suppl):314S-317S(1992).
[2] Moritoh, et al. Chronic administration of voglibose, an α-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J.Pharmacol.Exp.Ther. 329:669-676(2009).